| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 182.9 | 165.6 | 160.1 |
| Other income | 0.1 | 0.4 | 0.2 |
| Total income | 183.0 | 165.9 | 160.3 |
| Profit before exceptional items & tax | 15.7 | 4.6 | 15.2 |
| Profit before tax | 15.7 | 4.6 | 15.2 |
| Net profit | 11.9 | 3.2 | 15.2 |
| Operating margin | 8.6% | 2.8% | 9.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -21.70% |
|---|---|
| Net profit, quarter on quarter | +271.90% |
| Revenue, year on year | +14.20% |
| Operating profit, year on year | +4.00% |
| Operating profit, quarter on quarter | +271.40% |
NSE results filing, NSE: WANBURY. Figures extracted from the filing.
Wanbury Ltd: key numbers
- Share price
- ₹192.41
- Market cap
- ₹672.8 Cr
- Revenue (annual)
- ₹650.3 Cr
- Net profit (annual)
- ₹66.13 Cr
- P/E (TTM)
- 12.0×Sector 37.9×
- Promoter holding
- 42.98%-0.04% QoQ
- FII holding
- 0.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Wanbury Ltd
All →Wanbury Business Update
Wanbury's Tanuku plant received an Australian TGA GMP certificate covering six APIs. This strengthens the company's global pharmaceutical manufacturing credentials.
Wanbury Board Meeting Date
Wanbury Limited has scheduled its Board Meeting for 4 Nov 2026 to consider unaudited half-year results. No financial figures or material decisions are disclosed in this advance intimation.
Wanbury Other Announcement
Wanbury Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI listing regulations.
Wanbury Business Update
Wanbury Limited received nine "No DMF Deficiency" letters from the USFDA for Metformin HCl. The company also expanded its business in Saudi Arabia and Mexico with an annual revenue potential of Rs 25 Crore.
Wanbury Product Launch
Wanbury Skin Health launched its berrysoft baby product range across multiple Indian states. This marks the company's strategic entry into the paediatric dermatology segment.
Wanbury Business Update
Wanbury filed new Drug Master Files in South Africa, Philippines and Singapore for its APIs. It also added KSM vendors and received EDQM/TGA compliance clearances.